BioSpace News Archive

Axiom Communications, on behalf of Novel Drug Solutions, LLC and Eye Care Northwest, PA announced today that the companies have delivered a Notice of Termination and Cease and Desist directive to Harrow Health, Inc. (NASDAQ: HROW formerly known as Imprimis Pharmaceuticals, Inc.).

The Alaska Heart & Vascular Institute (AHVI) is Alaska’s leading provider of cardiovascular care.

UnitedHealthcare and Optum, the health benefits and services companies of UnitedHealth Group, are taking action to help people affected by recent severe weather and flooding across parts of Kansas.

Legwork, the leading cloud-based, all-in-one patient engagement and marketing automation software for dental practices, today announced they have secured $17 million in funding from Level Equity, a growth equity firm based in New York and San Francisco.

Tespo, a home health technology company, today announced that Nature Made-branded Tespo Pods are available for purchase.

Cenveo, a leading provider of transformative publishing solutions, today announced that their Code Book Printing Process* has earned certified status for information security by HITRUST.

The Patented Medicine Prices Review Board (PMPRB), through the National Prescription Drug Utilization Information System (NPDUIS) research initiative, today published the 2018 edition of Meds Pipeline Monitor

This meeting is being held to update shareholders on the current status of the company’s ongoing research projects.

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Jefferies 2019 Global Healthcare Conference at 10:30 a.m. ET on Thursday, June 6, 2019, in New York. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, of Neurocrine Biosciences will present at the conference.

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced the completion of its review of strategic alternatives, following which the Company’s Board of Directors is implementing a series of measures designed to extend Merrimack’s cash runway into 2027 and preserve its ability to capture the potential remaining ONIVYDE-related milestones resulting from its 2017 asset sale to Ipsen S.A